EP. 4: Capmatinib for MET Exon 14-Mutated NSCLC
April 5th 2021
Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.